AnaptysBio (ANAB) director Orwin updates stock options after separation

Rhea-AI Filing Summary

ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.

Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.

Insights

Equity compensation analyst

Form 4 shows option adjustments from a separation, not open‑market trading.

The filing for ANAPTYSBIO, INC details option grants and matching cancellations for director John A. Orwin. Footnotes tie these changes to a Separation and Distribution Agreement with First Tracks, where existing options were split into options for both companies.

The transactions include acquisitions (code A) and dispositions to the issuer (code D) of equal-sized option blocks at different exercise prices, indicating administrative restructuring rather than net new awards or sales. No open-market buys or sells are reported.

Because derivativeSummary is empty and each line’s post-transaction balance matches the grant size, this Form 4 mainly updates how past equity incentives are allocated after the separation. It is a routine structural change with neutral impact on AnaptysBio’s investment case.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider Orwin John A

Role null

Type	Security	Shares	Price	Value
Disposition	Stock Option (right to buy)	3,311	$0.00	--
Grant/Award	Stock Option (right to buy)	3,311	$0.00	--
Disposition	Stock Option (right to buy)	10,600	$0.00	--
Grant/Award	Stock Option (right to buy)	10,600	$0.00	--
Disposition	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Disposition	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Disposition	Stock Option (right to buy)	8,250	$0.00	--
Grant/Award	Stock Option (right to buy)	8,250	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 3,311 shares (Direct, null)

Footnotes (1)

1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant size: 8,250 options Option grant size: 16,510 options Option grant size: 16,510 options +4 more

7 metrics

Option grant size 8,250 options Stock Option grant at $32.17 exercise price

Option grant size 16,510 options Stock Option grant at $10.87 exercise price

Option grant size 16,510 options Stock Option grant at $15.53 exercise price

Option grant size 10,600 options Stock Option grant at $14.29 exercise price

Option grant size 3,311 options Stock Option grant at $14.29 exercise price

Earliest option expiration September 14, 2033 Expiration date for certain reported options

Latest option expiration January 6, 2036 Expiration date for certain reported options

Key Terms

Stock Option (right to buy), Disposition to issuer, Separation and Distribution Agreement, pro rata distribution, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Disposition to issuer financial

"transaction_code_description: Disposition to issuer"

Separation and Distribution Agreement financial

"pursuant to the Separation and Distribution Agreement dated as of April 20, 2026"

pro rata distribution financial

"Effective as of a pro rata distribution by AnaptysBio to holders"

A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Orwin John A

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.5	04/20/2026		D(1)			3,311	(2)	09/14/2033	Common Stock	3,311	$0	3,311	D
Stock Option (right to buy)	$14.29	04/20/2026		A(1)		3,311		(2)	09/14/2033	Common Stock	3,311	$0	3,311	D
Stock Option (right to buy)	$19.5	04/20/2026		D(1)			10,600	(2)	09/14/2033	Common Stock	10,600	$0	10,600	D
Stock Option (right to buy)	$14.29	04/20/2026		A(1)		10,600		(2)	09/14/2033	Common Stock	10,600	$0	10,600	D
Stock Option (right to buy)	$21.19	04/20/2026		D(1)			16,510	(2)	01/02/2034	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$15.53	04/20/2026		A(1)		16,510		(2)	01/02/2034	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$14.83	04/20/2026		D(1)			16,510	(2)	01/06/2035	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$10.87	04/20/2026		A(1)		16,510		(2)	01/06/2035	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$43.91	04/20/2026		D(1)			8,250	(3)	01/06/2035	Common Stock	8,250	$0	8,250	D
Stock Option (right to buy)	$32.17	04/20/2026		A(1)		8,250		(3)	01/06/2036	Common Stock	8,250	$0	8,250	D

Explanation of Responses:

1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.

2. The stock option is fully vested and exercisable.

3. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Dan Faga, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ANAPTYSBIO (ANAB) director John A. Orwin report?

John A. Orwin reported option grants and matching cancellations on April 20, 2026. He acquired several stock options to buy AnaptysBio common shares and simultaneously disposed of equal-sized, higher-strike options back to the issuer, reflecting an administrative restructuring of his equity awards.

Were there any open-market stock purchases or sales in this ANAB Form 4?

No open-market trades appear in this Form 4. All transactions involve derivative awards: stock option grants (code A) and dispositions to the issuer (code D). These entries reflect equity compensation and adjustments, not market purchases or sales of AnaptysBio common stock.

How is the AnaptysBio–First Tracks separation related to these ANAB option grants?

Footnotes state that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each outstanding AnaptysBio option was adjusted into options for both companies. As a result, John A. Orwin acquired new AnaptysBio options in amounts determined by that agreement.

What are the key exercise prices and sizes of John Orwin’s new ANAB stock options?

Reported option grants include 8,250 shares at an exercise price of $32.17, 16,510 shares at $10.87, 16,510 shares at $15.53, 10,600 shares at $14.29, and 3,311 shares at $14.29. Each corresponds to equal-sized cancellations of higher-strike options back to AnaptysBio.

How do the vesting terms work for the newly reported ANAB stock options?

One footnote states a stock option is fully vested and exercisable. Another explains a stock option vests 1/12 of the total shares monthly starting February 6, 2026, contingent on John A. Orwin continuing to provide service to AnaptysBio on each vesting date.

What expiration dates are disclosed for John Orwin’s AnaptysBio stock options?

The Form 4 lists expiration dates of January 6, 2036, January 6, 2035, January 2, 2034, and September 14, 2033 for different stock option grants. These dates mark the last days on which the respective options to buy AnaptysBio common stock can be exercised.